Extracellular Vesicles and Tunnelling Nanotubes as Mediators of Prostate Cancer Intercellular Communication
Biomolecules · 2024
DOI: 10.3390/biom15010023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Jessica K Heatlie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Extracellular Vesicles, Prostatic Neoplasms, Cell Communication, Nanotubes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Envision Sciences Pty Ltd., University of South Australia Postgraduate Award (USAPA).
Abstract (Originalsprache)
Prostate cancer (PCa) pathogenesis relies on intercellular communication, which can involve tunnelling nanotubes (TNTs) and extracellular vesicles (EVs). TNTs and EVs have been reported to transfer critical cargo involved in cellular functions and signalling, prompting us to investigate the extent of organelle and protein transfer in PCa cells and the potential involvement of the androgen receptor. Using live cell imaging microscopy, we observed extensive formation of TNTs and EVs operating between PCa, non-malignant, and immune cells. PCa cells were capable of transferring lysosomes, mitochondria, lipids, and endoplasmic reticulum, as well as syndecan-1, sortilin, Glut1, and Glut4. In mechanistic studies, androgen-sensitive PCa cells exhibited changes in cell morphology when stimulated by R1881 treatment. Overexpression assays of a newly designed androgen receptor (AR) plasmid revealed its novel localization in PCa cellular vesicles, which were also transferred to neighbouring cells. Selected molecular machinery, thought to be involved in intercellular communication, was investigated by knockdown studies and Western blotting/immunofluorescence/scanning electron microscopy (SEM). PCa TNTs and EVs transported proteins and organelles, which may contain specialist signalling, programming, and energy requirements that support cancer growth and progression. This makes these important intercellular communication systems ideal potential targets for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
- Department of Histopathology, Trinity College Dublin, D02 PN40 Dublin, Ireland.
- South Australian ImmunoGENomics Cancer Institute and Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA 5005, Australia.
- Solid Tumour Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.
ORCID-Profile: Jessica K Heatlie, Courtney R Moore, Ian R D Johnson, Bukuru D Nturubika, Ruth Williams, Mark P Ward, John J O'Leary, Lisa M Butler, Doug A Brooks
Förderung
- Envision Sciences Pty Ltd.
- University of South Australia Postgraduate Award (USAPA)
Zitieren
APA
Heatlie, J. K., Lazniewska, J., Moore, C. R., Johnson, I. R. D., Nturubika, B. D., Williams, R., Ward, M. P., O'Leary, J. J., Butler, L. M., & Brooks, D. A. (2024). Extracellular Vesicles and Tunnelling Nanotubes as Mediators of Prostate Cancer Intercellular Communication. Biomolecules. https://doi.org/10.3390/biom15010023
Vancouver
Heatlie JK, Lazniewska J, Moore CR, Johnson IRD, Nturubika BD, Williams R, et al. Extracellular Vesicles and Tunnelling Nanotubes as Mediators of Prostate Cancer Intercellular Communication. Biomolecules. 2024. doi:10.3390/biom15010023
BibTeX
@article{Heatlie2024,
author = {Heatlie, Jessica K and Lazniewska, Joanna and Moore, Courtney R and Johnson, Ian R D and Nturubika, Bukuru D and Williams, Ruth and Ward, Mark P and O'Leary, John J and Butler, Lisa M and Brooks, Doug A},
title = {Extracellular Vesicles and Tunnelling Nanotubes as Mediators of Prostate Cancer Intercellular Communication},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom15010023}
}
EUVIMED